- Home
- RCKY vs DSGN Comparison
RCKY vs DSGN Comparison
Compare RCKY & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKY
- DSGN
- Stock Information
- Founded
- RCKY 1932
- DSGN 2017
- Country
- RCKY United States
- DSGN United States
- Employees
- RCKY N/A
- DSGN N/A
- Industry
- RCKY Shoe Manufacturing
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- RCKY Consumer Discretionary
- DSGN Health Care
- Exchange
- RCKY Nasdaq
- DSGN Nasdaq
- Market Cap
- RCKY 196.3M
- DSGN 208.9M
- IPO Year
- RCKY 1993
- DSGN 2021
- Fundamental
- Price
- RCKY $30.27
- DSGN $5.43
- Analyst Decision
- RCKY Buy
- DSGN
- Analyst Count
- RCKY 1
- DSGN 0
- Target Price
- RCKY $40.00
- DSGN N/A
- AVG Volume (30 Days)
- RCKY 81.7K
- DSGN 136.8K
- Earning Date
- RCKY 07-29-2025
- DSGN 08-07-2025
- Dividend Yield
- RCKY 2.07%
- DSGN N/A
- EPS Growth
- RCKY 24.23
- DSGN N/A
- EPS
- RCKY 2.48
- DSGN N/A
- Revenue
- RCKY $462,328,000.00
- DSGN N/A
- Revenue This Year
- RCKY $7.02
- DSGN N/A
- Revenue Next Year
- RCKY $3.96
- DSGN N/A
- P/E Ratio
- RCKY $12.08
- DSGN N/A
- Revenue Growth
- RCKY N/A
- DSGN N/A
- 52 Week Low
- RCKY $11.93
- DSGN $2.60
- 52 Week High
- RCKY $33.04
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- RCKY 70.80
- DSGN 62.09
- Support Level
- RCKY $25.76
- DSGN $4.92
- Resistance Level
- RCKY $31.30
- DSGN $5.41
- Average True Range (ATR)
- RCKY 1.08
- DSGN 0.37
- MACD
- RCKY 0.26
- DSGN 0.03
- Stochastic Oscillator
- RCKY 84.75
- DSGN 84.66
About RCKY Rocky Brands Inc.
Rocky Brands Inc acts as a designer, manufacturer, and marketer of premium-quality footwear and apparel. The company's family of brands includes Rocky, Georgia Boot, Durango, Lehigh, Creative Recreation, and the licensed brand Michelin footwear. The company operates its business through three business segments: Wholesale, Retail and Contract Manufacturing. It generates the majority of the revenue from the Wholesale segment.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.